Tyrosine kinase inhibitor use in idiopathic pulmonary fibrosis
نویسندگان
چکیده
منابع مشابه
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
BACKGROUND Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS In a 12-month, phase 2 trial, we assessed...
متن کاملPulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis: A Chance for a Multidisciplinary Treatment Approach
Background and Objectives: Idiopathic pulmonary fibrosis (IPF) is characterized by progressively worsening lung function, ventilation capacity, dyspnea, and finally reduced exercise intolerance. All of these have a significant negative impact on functional capacity and quality of life. In this study, we aim to evaluate the effects of pulmonary rehabilitation (PR) in IPF and assess the predictor...
متن کاملPediatric Idiopathic Pulmonary Fibrosis: A Case Series report
Khalilzadeh S1, Baghaei N2, Bolorsaz MR1, Masjedi MR3 1. Associate professor, Department of pediatrics, Education, research and treatment center of tuberculosis and long diseases, Shahid Beheshti University of medical sciences 2. Assistant professor, Department of pediatrics, Education, research and treatment center of tuberculosis and long diseases, Shahid Beheshti University of medical s...
متن کاملREPORT OF FOUR CASES OF FAMILIAL IDIOPATHIC PULMONARY FIBROSIS
A 25 year old male and his 46 year old aunt presented with shortness of breath and a dramatic response to steroids. The other two patients are sisters with more advanced disease. One of these responded partially to steroids, while the other died within 4 months of treatment. The genetic basis and pathogenesis are discussed.
متن کاملClinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Hajari Case A, Johnson P. BMJ Open Resp Res 2017;4:e000192. doi:10.1136/bmjresp-2017-000192 AbstrAct Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Thorax
سال: 2011
ISSN: 0040-6376,1468-3296
DOI: 10.1136/thoraxjnl-2011-201439